Investor: ARCH Venture Partners
Syndex Bio has secured £11.5 million in Seed funding led by ARCH Venture Partners. Summary of transaction details: Value: £11.5 million Sector: Healthcare & Biotech Advisor: N/A Key Entities: Syndex Bio, ARCH Venture Partners Location: Cambridge, UK Note: This investment will enable Syndex Bio to further develop its proprietary mcPCR platform, advancing next-generation molecular diagnostics.
Sign in to view financial history
Sign in to view directors and officers
Sign in to view company news
Install PE Deals
Open it from your home screen or desktop, no tab needed.
